News

1) Another ophthalmology acquisition: Oculis. SA and European Biotech Acquisition Corp. announce business combination agreement The resultant company, Oculis Holding SA will work to accelerate the development of Oculis’s differentiated ophthalmology pipeline therapeutics for diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma. Oculis’ pipeline includes

1) Eli Lilly (NYSE: LLY) enters into collaboration with Nimbus to develop therapeutics for metabolic diseases Eli Lilly and Nimbus enter into a collaboration to develop therapeutics for metabolic diseases. The two companies will collaborate on the development of novel targeted therapies designed to activate a specific isoform of AMPK

1) Bristol Myers Squibb (BMS) enters into 2 licensing deals with SynethX and Autolus Therapeutics (AUTL) Bristol Myers Squibb (NYSE: BMS) entered into 2 licensing deals with SynethX Inc and Autolus Therapeutics (NASDAQ: AUTL). The first deal is with SynethX which will focus on discovering molecular glue degraders. Synethx has

1) Eisai and Biogen Report Positive Phase III Data for Anti-Amyloid Alzheimer's Drug Eisai and Biogen announced that the duo’s Alzheimer's drug, Lecanemab, slowed the rate of cognitive decline for early Alzheimer’s participants in the phase 3 clinical trial by 27% compared to a

1. Iveric plans FDA submission of data for geographic atrophy eye-drug following study success Iveric Bio announced positive phase 3 topline data from Zimura for geographical atrophy (GA). Zimura is a novel investigational complement C5 inhibitor. Overactivity of the complement system and the C5 protein are suspected to play a

1. FDA clears updated COVID-19 boosters from Pfizer, Moderna A long-awaited moment! On Wednesday, FDA approved a new version of Pfizer’s vaccine for adults and children over 12 years old and Moderna’s modified shot for adults who are 18 or older. Both vaccines are bivalent, meaning that they